Amgen files lawsuit against Regeneron, Sanofi to avoid infringing manufacture of alirocumab Amgen today announced that it filed a lawsuit in the United States , and Regeneron Pharmaceuticals, Inc. for patent infringement of U.S www.tadalafilmed.com http://tadalafilmed.com . Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and state monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 . By its complaint, Amgen seeks an injunction to avoid the infringing manufacture, make use of and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced they have completed Stage 3 medical trials on alirocumab and plan to pursue regulatory approval to market alirocumab in the U.S.